1-866-598-7166

Trials for patients who have had previous drug treatment

9-ING-41 in Patients with Advanced Cancers

[vc_row][vc_column][vc_column_text css=""] Background: A protein called GSK-3β plays a role in cancer by helping cancer cells grow, survive, and resist treatment. High levels of this protein have been found in many different cancers.  9-ING-41 is a new type of drug that blocks GSK-3β. Earlier lab studies have found...

Stereotactic Radiation Therapy (SABR) With or Without Immunotherapy for Patients With Unresectable or Metastatic Kidney Cancer (SAMURAI)

[vc_row][vc_column][vc_column_text css=""] Background: Stereotactic body radiation therapy (SABR) is a type of radiation therapy that uses special equipment to deliver radiation to tumors with high precision. This method may kill tumor cells with few radiation doses over a shorter period, causing less damage to normal tissue.  Immunotherapy, such...

A Study of MK-4700 Alone or With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

[vc_row][vc_column][vc_column_text css=""] Background: MK-4700 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies. Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works...

A Study of BMS-986488 as Monotherapy and Combination Therapy in Patients with Advanced Malignant Tumors

[vc_row][vc_column][vc_column_text css=""] Background: BMS-986488 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies. Nivolumab (Opdivo®) is an immunotherapy that works by boosting the body's immune system to recognize and attack cancer cells. Since this...

A Study of 23ME-00610 in Patients with Advanced Kidney Cancer

Background: 23ME-00610 belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Some notable approved immune checkpoint inhibitors for kidney cancer include Nivolumab (Opdivo®), Ipilimumab (Yervoy®),...

Kidney Cancer Canada